M.J. Biopharm Private Limited: Company Profile
Background
Established in 2002, M.J. Biopharm Private Limited is a biopharmaceutical company specializing in the production of medical formulations targeting a range of ailments, with a particular emphasis on diabetes management. The company's mission is to enhance healthcare by developing and providing high-quality, cost-effective biopharmaceutical products. Over the years, M.J. Biopharm has expanded its global footprint, with its pharmaceutical formulations accredited and sold in over 30 countries.
Key Strategic Focus
M.J. Biopharm's strategic focus centers on the development and manufacturing of biosimilars and biopharmaceutical formulations, particularly injectable life-saving products. The company's core product is human recombinant DNA insulin, available in various dosage forms such as injectable cartridges, vials, and disposable pen devices. By leveraging a microbial platform, M.J. Biopharm aims to develop various insulin analog formulations that reduce costs for patients through economical production of biosimilar products.
Financials and Funding
As of the fiscal year ending March 31, 2023, M.J. Biopharm reported a 15.73% increase in total revenue and a 27.68% rise in profit compared to the previous year. The company's net worth also saw a moderate increase of 9.38%. The authorized share capital stands at ₹40.00 crore, with a paid-up capital of ₹23.01 crore. The company has active open charges totaling ₹151.00 crore, indicating ongoing financial commitments.
Pipeline Development
M.J. Biopharm's research and development efforts are focused on advancing biotechnological research from concept to commercialization. The company is working on new-generation anti-diabetic treatments, including DPP-4 inhibitors and GLP-1 analogs. Collaborations with global partners aim to develop drug delivery systems that extend the therapeutic action of GLP-1 from 12 hours to one week.
Technological Platform and Innovation
The company operates two state-of-the-art manufacturing facilities:
- Taloja Facility: Located near Mumbai, this WHO GMP-certified facility complies with PIC standards and produces a range of injectables in various forms, including ampoules, vials, cartridges, and pre-filled syringes.
- Pune Facility: Situated in the MIDC biotech park zone in Hinjewadi, Pune, this modern biotech facility is built according to standards set by the European Medicines Evaluation Agency (EMEA) and the US FDA. It is equipped for microbial products with fermentation and downstream sections, featuring fully automated, PLC-based systems and clean rooms controlled by a Building Management System (BMS).
M.J. Biopharm's R&D team possesses expertise in transferring molecules from preclinical development to Phase III clinical trials, focusing on developing stable and biosimilar formulations of synthetic peptides and r-DNA peptides. The company employs a Quality by Design approach in formulation development and technology transfer, ensuring compliance with US, EU, and Indian Pharmacopeia standards.
Leadership Team
- Amol Shah: Managing Director since January 1997, Amol Shah holds an OPM in Business Administration and Management from Harvard Business School Executive Education, an MBA in Marketing from USC Marshall School of Business, and a BE in Electronics Engineering from the University of Kent.
- Pheroze Mistry: Director, contributing to the company's strategic direction.
- Kajal Shah: Director, involved in overseeing company operations.
- Pradakshina Goswami: Company Secretary, responsible for corporate governance and compliance.
Competitor Profile
Market Insights and Dynamics
The global biopharmaceutical market is experiencing significant growth, driven by increasing prevalence of chronic diseases such as diabetes and cardiovascular conditions. The demand for biosimilars and cost-effective biopharmaceuticals is on the rise, presenting opportunities for companies like M.J. Biopharm to expand their market share.
Competitor Analysis
Key competitors in the biopharmaceutical sector include:
- Biocon Limited: An Indian biopharmaceutical company specializing in diabetes and oncology treatments.
- Wockhardt Limited: A global pharmaceutical and biotechnology company with a focus on biopharmaceuticals.
- Lupin Limited: A multinational pharmaceutical company with a strong presence in the biopharmaceutical segment.
These competitors have established market positions and continue to invest in research and development to expand their product portfolios.
Strategic Collaborations and Partnerships
M.J. Biopharm has engaged in collaborations with global partners to develop advanced drug delivery systems, particularly focusing on extending the therapeutic action of GLP-1 analogs. These partnerships aim to enhance the company's product offerings and provide innovative solutions for diabetes management.
Operational Insights
The company's export-based business strategy has been key to its growth, with global footprints in countries across Asia Pacific, Africa, Eurasia, and Latin America. M.J. Biopharm's commitment to quality is evident in its WHO GMP-certified facilities and adherence to international standards, providing a competitive advantage in the biopharmaceutical market.
Strategic Opportunities and Future Directions
M.J. Biopharm aims to expand its presence in regulated markets by completing its expansion project in Pune, targeting additional capacities and economies of scale. The company continues to invest in R&D and regulatory practices to create a robust product pipeline, focusing on new-generation anti-diabetic treatments and innovative drug delivery systems.
Contact Information
- Website: mjgroup.co.in
- LinkedIn: linkedin.com/company/mjbiopharm
- Twitter: twitter.com/mjbiopharm
- Facebook: facebook.com/mjbiopharm
M.J. Biopharm Private Limited continues to build on its rich heritage, focusing on innovation and quality to provide life-saving biopharmaceutical products globally.
